Zobrazeno 1 - 10
of 26
pro vyhledávání: ''
Publikováno v:
Breast Disease. 40:S33-S37
BACKGROUND: Increased plasma aldehyde dehydrogenase 1 (ALDH1) levels have been proposed to predict cancer chemoresistance. However, studies have reported inconsistent results, depending on the type of cancer cells used. OBJECTIVE: This study aimed to
Publikováno v:
Breast Disease. 40:25-31
AIM OF THE STUDY: The microenvironment depicts the relationship between tumour cells and immune response, and every insight into stromal lymphocytes could contribute to explain their role and activity. E26 transformation specific-1 (ETS-1) is a trans
Autor:
Sofia Lizandro, Joseph A. Pinto, Silvia P. Neciosup, Renato Luque, María G. Luján-Peche, Zaida Morante, Daniel J Enriquez, Antonella Saavedra, Miguel Eduardo Eyzaguirre-Sandoval, Cesar Razuri, Bryan Valcarcel, Lia P. Rebaza, Henry L. Gomez, Mecker G. Möller, Hugo Fuentes, Gabriel De-la-Cruz-Ku
Publikováno v:
Breast Disease. 39:29-35
Background Breast-conserving surgery (BCS) as an alternative to total mastectomy (TM) in patients with early-stage triple-negative breast cancer (TNBC) is not widely spread. Objective We aimed to compare the overall survival (OS) and disease-free sur
Publikováno v:
Breast Disease. 38:7-13
Background Positive margins after Breast conserving surgery (BCS) for breast cancer can result in local recurrence (LR) requiring further surgery. This can lead to unnecessary patient anxiety, poor prognosis and impose additional economic burden to o
Autor:
Ho Kyung Hwang, Young Ki Paik, Sung Hyun Kim, Min Jung Lee, Chang Moo Kang, Sung Hwan Lee, Hoguen Kim
Publikováno v:
Cancer Biomarkers. 24:335-342
Background For patients with pancreatic cancer, a preoperative assessment of prognosis is crucial to predict cancer recurrence and to prepare a postoperative adjuvant strategy and appropriate patient-counsel. Objective We evaluated the prognostic pre
Autor:
Mayuko Nishi, Masatsugu Iwamura, Yuichi Sato, Noriyuki Amano, Masaomi Ikeda, Kazumasa Matsumoto, Ryo Nagashio, Megumi Nomura, Akihide Ryo, Yuriko Shimizu
Publikováno v:
Cancer Biomarkers. 24:91-96
BACKGROUND New biomarkers may help us provide individualized prognosis and allow risk-stratified clinical decision making about radical treatment. OBJECTIVES This study aimed to determine the tumor necrosis factor of receptor superfamily 19 (TROY) ex
Publikováno v:
Cancer Biomarkers. 23:485-494
OBJECTIVE This study aimed to explore the correlation of long non-coding RNA taurine-upregulated gene 1 (lncRNA TUG1) expression with clinicopathological features and its predictive value for treatment response and survival profiles in refractory or
Publikováno v:
Cancer Biomarkers. 23:213-220
Objective Lymphoma is considered to be a kind of malignant tumour. Gene therapy and radiotherapy have been reported as treatment methods for head and neck lymphoma. This study aims to evaluate the efficacy and safety for the treatment of head and nec
Autor:
Meina Wu, Ziping Wang, Jun Zhao, Jia Zhong, Xue Yang, Yuyan Wang, Hanxiao Chen, Jing Huang, Minglei Zhuo, Tianzhuo Zhang, Tongtong An
Publikováno v:
Cancer Biomarkers. 22:467-476
BACKGROUND The PD-L1 antibody atezolizumab has shown promising efficacy in patients with advanced non-small cell lung cancer. But the predictive marker of clinical benefit has not been identified. OBJECTIVE This study aimed to search for potential pr
Publikováno v:
Cancer Biomarkers. 22:405-415
Neoadjuvant chemotherapy (NCT) is the standard treatment for locally advanced breast cancer (LABC). Pathological complete response (pCR) is commonly used as a valid predictor of NCT long-term outcomes. Blood-based tumor biomarkers have the potential